Device encapsulated MSCs for adaptive secretome therapy to effectively target ischaemic heart injury.

ABSTRACT:

Background

Effective long-term strategies to protect the ischaemic heart remain a significant challenge. Mesenchymal stromal cells (MSCs) offer therapeutic potential primarily through their secretome, a bioactive factor-rich milieu with broad beneficial effects. However, existing delivery methods have not demonstrated sustained cardioprotection. The objective of this study was to evaluate a clinically translatable approach for sustained MSC-secretome delivery to achieve long-term cardioprotection.

Methods

Cymerus MSCs, derived from human induced pluripotent stem cells (iPSCs), were encapsulated in a Procyon immunoisolation device and implanted subcutaneously in adult Sprague Dawley rats with chronic myocardial ischaemia-reperfusion injury. A human iPSC-derived engineered car

SUBMITTER: Kompa AR 

PROVIDER: S-EPMC12797737 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature